The Top 5 Biosimilars Articles for the Week of January 6

January 11, 2020

The Center for Biosimilars® recaps the top stories for the week of January 6.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 6, 2019.

Number 5: A recent study finds that peer influence factors heavily into whether oncologists decide to adopt bevacizumab for their patients.

Number 4: The FDA notes the approval of 10 biosimilars in its 2019 report of drug approvals, which included 48 novel drugs.

Number 3: A look back at the top 5 legal stories in 2019 finds that cases involving adalimumab featured in 2 of them.

Number 2: Novo Nordisk takes 3 steps to improve insulin affordability, and says the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.

Number 1: Pfizer says it is launching its bevacizumab biosimilar, Zirabev, in the United States.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Practice | Legal | Endocrinology | Oncology

x